|
|
Volumn 75, Issue 1, 2019, Pages 201-203
|
|
An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CISPLATIN;
DURVALUMAB;
GEMCITABINE;
PACLITAXEL;
PROGRAMMED DEATH 1 LIGAND 1;
TICILIMUMAB;
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
ADULT;
ADVANCED CANCER;
ADVERSE EVENT;
CANCER CHEMOTHERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CANCER PATIENT;
CLINICAL ARTICLE;
CLINICAL FEATURE;
CONTROLLED STUDY;
DISEASE EXACERBATION;
FOLLOW UP;
GERM CELL TUMOR;
HUMAN;
LETTER;
MALE;
MICROSATELLITE INSTABILITY;
MONOTHERAPY;
MULTIPLE CYCLE TREATMENT;
OPEN STUDY;
PHASE 2 CLINICAL TRIAL;
PRIMARY TUMOR;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;
SAMPLE SIZE;
SEMINOMATOUS GERMINOMA;
TREATMENT RESPONSE;
CLINICAL TRIAL;
LUNG TUMOR;
NEOPLASM;
PATHOLOGY;
SECONDARY;
SEMINOMA;
TESTIS TUMOR;
TREATMENT FAILURE;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
HUMANS;
LUNG NEOPLASMS;
MALE;
NEOPLASMS, GERM CELL AND EMBRYONAL;
SEMINOMA;
TESTICULAR NEOPLASMS;
TREATMENT FAILURE;
|
|
EID: 85057850363
PISSN: 03022838
EISSN: 18737560
Source Type: Journal
DOI: 10.1016/j.eururo.2018.09.010 Document Type: Letter |
|
Times cited : (55)
|
|
References (5)
|
